Physician profile
Abboud Hanna
NPI 1922237072
$8,437.95
in general payments reported to CMS, 2019-2025
30 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,578 · 2020: $1,190 · 2021: $1,065 · 2022: $935 · 2023: $1,052 · 2024: $941 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.47 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,211.51 | 2019-2025 | Lokelma |
| Alexion Pharmaceuticals, INC. | $674.07 | 2019-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $547.98 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $488.81 | 2019-2023 | Jynarque |
| Vifor Pharma, INC. | $452.22 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $406.31 | 2019 | |
| Amgen INC. | $395.30 | 2022-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $391.17 | 2020-2025 | Terlivaz, Acthar |
| Portola Pharmaceuticals, LLC | $365.69 | 2020 | |
| Janssen Pharmaceuticals, INC | $345.83 | 2019-2020 | |
| Horizon Therapeutics Plc | $337.81 | 2020-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $334.75 | 2019-2024 | Velphoro |
| Travere Therapeutics, INC. | $281.59 | 2023-2024 | |
| Opko Pharmaceuticals, LLC | $264.79 | 2019-2021 | |
| Novo Nordisk INC | $229.17 | 2023-2024 | Wegovy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $211.05 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.51 | 2020-2022 | |
| Abbott Laboratories | $184.86 | 2019 | |
| Glaxosmithkline, LLC. | $136.85 | 2020-2021 | |
| Baxter Healthcare | $127.51 | 2024 | |
| Pfizer INC. | $121.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.58 | 2019 | |
| Lilly USA, LLC | $119.05 | 2025 | |
| Allergan, INC. | $101.17 | 2019 | |
| Nxstage Medical, INC. | $97.57 | 2022-2023 | Liberty Select Cycler |
| Actelion Pharmaceuticals US, INC. | $96.80 | 2019 | |
| Philips North America LLC | $73.99 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $52.21 | 2019-2020 | |
| Daiichi Sankyo INC. | $44.55 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $33.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abboud Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.